SCHEDULE 13G/A 0001035674 XXXXXXXX LIVE 3 Common Stock, $0.0001 par value per share 12/31/2025 0001157601 Madrigal Pharmaceuticals, Inc. 558868105 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 Rule 13d-1(c) PAULSON & CO. INC. b DE 1707522 0 1707522 0 1707522 7.5 IA Items 5, 7 & 9 (See Note 1 to Item 4 below) Madrigal Pharmaceuticals, Inc. Four Tower Bridge, 200 Barr Harbor Drive, Suite 200 West Conshohocken, PA 19428 Paulson & Co. Inc. (the "Reporting Person") 15 Exchange Place, Jersey City, New Jersey 07302 Delaware corporation Y 1,707,522 7.5% 1,707,522 (See Note 1) 0 1,707,522 (See Note 1) Shared power to dispose or to direct the disposition of is 0. The aggregate percentage of Common Stock reported owned by each person named herein is based upon 22,711,420 shares of Common Stock outstanding as of October 30, 2025, which is the total number of shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2025. Note 1: Paulson & Co. Inc. ("Paulson") and its affiliates furnish investment advice to and manage onshore and offshore investment funds and separate managed accounts (such investment funds and accounts, the "Funds"). In its role as investment advisor, or manager, Paulson possesses voting and-or investment power over the securities of the Issuer described in this schedule that are owned by the Funds. All securities reported in this schedule are owned by the Funds. Paulson disclaims beneficial ownership of such securities. Y N All securities reported in this schedule are owned by Paulson's advisory clients, none of which to Paulson's knowledge owns more than 5% of the class. Paulson itself disclaims beneficial ownership of all such securities. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. PAULSON & CO. INC. PAULSON & CO. INC. 02/17/2026